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Objective: To compare NASHA hyaluronic acid gel as single-injection intra-articular (IA) treatment for
knee osteoarthritis (OA) against methylprednisolone acetate (MPA).
Design: This was a prospective, multi-centre, randomized, active-controlled, double-blind, non-
inferiority clinical trial. A unique, open-label extension phase (OLE) was undertaken to answer further
important clinical questions. Subjects with painful unilateral knee OA were treated and followed for 26
weeks (blinded phase). All patients attending the clinic at 26 weeks were offered NASHA treatment, with
a subsequent 26-week follow-up period (extension phase). The primary objective was to show non-
inferiority of NASHA vs MPA in Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) pain responder rate (percentage of patients with 40% improvement from baseline in
WOMAC pain score and an absolute improvement of 5 points) at 12 weeks.
Results: In total, 442 participants were enrolled. The primary objective was met, with NASHA producing
a non-inferior response rate vs MPA at 12 weeks (NASHA: 44.6%; MPA: 46.2%; difference [95% CI]: 1.6%
[11.2%; þ7.9%]). Effect size for WOMAC pain, physical function and stiffness scores favoured NASHA over
MPA from 12 to 26 weeks. In response to NASHA treatment at 26 weeks, sustained improvements were
seen in WOMAC outcomes irrespective of initial treatment. No serious device-related adverse events
(AEs) were reported.
Conclusions: This study shows that single-injection NASHAwas well tolerated and non-inferior to MPA at
12 weeks. The beneﬁt of NASHA was maintained to 26 weeks while that of MPA declined. An injection of
NASHA at 26 weeks conferred long-term improvements without increased sensitivity or risk of
complications.
Study identiﬁer: NCT01209364 (www.clinicaltrials.gov).
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Intra-articular hyaluronic acid (IA HA) is an established treat-
ment for knee osteoarthritis (OA), offering a useful option that lies
between analgesic treatment and joint replacement. The options
for pharmacological analgesic therapy include simple analgesics,R. Leighton, QEII Health Sci-
reet, Halifax, NS, Canada B3H
eighton).
s Research Society International. Pnon-steroidal anti-inﬂammatory drugs (NSAIDs) and cyclo-
oxygenase type 2 (COX-2) inhibitors. However, these treatments
are associated with potential safety concerns1e4. IA corticosteroids,
another treatment option for knee OA, are believed to have a faster
onset of action than HA but a shorter duration of effect5,6, and
repeated use of corticosteroids may be associated with increased
side effects7,8.
NASHA is a unique HA product whose production process begins
with bacterial synthesis of HA. This is followed by puriﬁcation and
then a carefully controlled stabilization process involving a small
degree of molecular cross-linking (w1%)9. The resulting NASHA gelublished by Elsevier Ltd. All rights reserved.
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and a prolonged IA residence time: the half-life in both the human
knee and a pre-clinical model is around 4 weeks10,11.
NASHA is administered as a single IA injection. Previous studies
in knee OA have demonstrated that NASHA provides signiﬁcant
post-treatment beneﬁts, lasting for at least 6 months12,13. NASHA
has also been shown to provide similar beneﬁt to the corticosteroid
triamcinolone acetonide (TA) in a 12-week study14.
The corticosteroid methylprednisolone acetate (MPA),
commonly used for IA treatment of OA15, has lower solubility than
unmodiﬁed methyprednisolone16. Few high-quality clinical studies
have compared the effects of different corticosteroid preparations
in knee OA. However, there is evidence that MPAmay have a longer
duration of effect than other corticosteroids17.
We performed a 26-week study to compare the effectiveness
and safety of a single IA injection of NASHA with MPA, which may
be considered as a standard-of-care treatment. The study hypoth-
esis was that NASHA is at least as effective as MPA for the treatment
of knee OA. A non-inferiority study design was chosen because the
only previous comparison of NASHA with IA corticosteroid (study
duration: 12 weeks), showed lack of statistically signiﬁcant efﬁcacy
differences between the two treatments. Although IA corticoste-
roids may be perceived as having a short duration of action
(4 weeks or less)6, there is evidence that they can provide symp-
tomatic improvement for 16e24 weeks18. At the end of the double-




This was a prospective, multi-centre, randomized (1:1),
corticosteroid-controlled, double-blind, non-inferiority clinical
study with an open-label extension phase (OLE), performed in
patients with knee OA. The initial blinded phase included a
26-week follow-up period. This was followed by unblinded NASHA
treatment and a further 26-week follow-up period (OLE). The study
was performed in accordance with the Declaration of Helsinki, the
International Conference on Harmonization Guidelines for Good
Clinical Practice, and applicable regulatory requirements. The re-
sults are presented in line with guidelines from Consolidated
Standards of Reporting Trials (CONSORT)19 and International
Committee of Medical Journal Editors (ICMJE)20. The study protocol
was reviewed and approved by Independent Ethics Committees/
Institutional Review Boards at each participating site. Signed
informed consent was obtained from each patient.
Study objectives
The primary objective was to determine whether NASHA is non-
inferior to MPA in Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) pain responder rate (deﬁned as an
improvement from baseline of at least 40% and an absolute
improvement of ﬁve points), at 12 weeks post-treatment. A pre-
deﬁned margin for non-inferiority was implemented (lower bound
of the two-sided 95% conﬁdence interval (CI) for between-group
difference above 15%). Secondary objectives were to assess the
safety and effectiveness of NASHA comparedwithMPA, during both
the blinded phase and the OLE.
Participants
Men andwomen aged 35e80with a bodymass index of40 kg/
m2, the ability to walk 50 m unaided, unilateral knee pain meetingthe American College of Rheumatology criteria for the diagnosis of
OA21, WOMAC pain score of 7e17 in the study knee, and radio-
graphically veriﬁed OA of the study knee (KellgreneLawrence
grade II or III; severity consistent with several trials demonstrating
the efﬁcacy of IA corticosteroids6), were recruited for the study. Key
exclusion criteria were: clinically detectable knee effusion, clini-
cally signiﬁcant contralateral knee OA (WOMAC pain score >3),
clinically signiﬁcant pain in joints other than the knee, IA steroid
injection into the study knee within the preceding 3 months, IA HA
injection into the study knee within the preceding 9 months, use of
systemic glucocorticosteroids (excluding inhaled steroids) within
the preceding 3 months and arthroscopy or other surgical proce-
dure in the study knee within the preceding 12 months. Study
participants were enrolled at each centre by staff other than the
treating investigator (usually it was the evaluating investigator). A
total of 442 participants were enrolled at sites in Canada (15 sites,
284 participants), UK (four sites, 36 participants) and Sweden (ﬁve
sites, 122 participants). The ﬁrst patient was screened on March 27,
2007 and the study was stopped when the last patient completed
the 52-week visit on November 12, 2008.Study treatments
For the blinded phase, eligible patients were randomized 1:1 to
receive a single IA injection of either NASHA (Q-Med AB, Uppsala,
Sweden; DUROLANE 60 mg in 3 mL) or MPA (1 mL, 40 mg; dose
consistent with several trials demonstrating the efﬁcacy of MPA6).
The randomization scheme was computer-generated by a contract
research organisation using a block-size of 4 stratiﬁed by site.
Identities of both the study and reference product were concealed
by packaging them in identical boxes labelled with the subject
number. Patient numbers were assigned sequentially as subjects
were randomized at each site. Prior to IA injection, synovial ﬂuid
was aspirated as needed and IA injection of lidocaine (2 mL, 1%
solution) was performed. IA injection was performed using one of
three techniques without ﬂuoroscopic or ultrasound guidance:
lateral upper-patellar, lateral mid-patellar or medial IA. The
treating investigator opened the treatment package before treat-
ment, but kept the identity of the treatment concealed from other
study staff (e.g., evaluating investigator). Blinding of study par-
ticipants was ensured by using drapes to prevent them from
viewing the injection procedure. The treating investigator was
allowed to perform some of the screening assessments, as well as
all of the injection-related procedures, but they were not allowed
to perform any effectiveness evaluations or assessments after the
patient had been randomized and treated. The assessment
schedule consisted of a screening visit (Visit 1), a baseline visit
during which the IA injections were administered (Visit 2), tele-
phone calls at 2 and 4 weeks post-injection to evaluate safety and
concomitant medication use, and clinic visits at 6, 12, 18 and
26 weeks post-injection to conduct effectiveness and safety as-
sessments (Visits 3e6). Rescue medication with acetaminophen
was allowed at up to 3 g per day.
The OLE was uniquely designed to answer two questions: can
one injection cause sensitivity to the second injection, and what are
the beneﬁts of a second injection? Subjects attending the 26-week
visit were offered a single, unblinded IA injection of NASHA,
administered using the samemethod as in the blinded phase. Clinic
visits for the OLE were scheduled at 28 weeks, 39 weeks and 52
weeks after the initial injection. The patient, treating investigator
and assessing investigator remained unaware of which treatment
was administered at the ﬁrst injection. Patients not requesting a
second injection were also followed to 52 weeks if their WOMAC
pain score was improved from baseline at the 26-week visit.
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TheWOMAC index (Likert format, version 3.1) was administered
with three domains: pain (ﬁve items, score 0e20), stiffness (two
items, score 0e8) and physical function (17 items, score 0e68);
items were assessed for the preceding 48 h. Patients’ assessment of
global status was recorded on a ﬁve-point scale. Physical activity
was assessed by each patient at baseline using a four-point scale;
subsequent assessments were made relative to baseline using a
ﬁve-point scale. Two additional functional assessments were per-
formed. Firstly, for ‘Get up and go’, the patient was timed while
rising from a chair, walking four paces, returning, and sitting down
again. Secondly, for ‘10-m timed walk’, the patient was timed while
walking 10 m. Rescue medication was recorded as the number of
tablets taken since the last study visit and the number of tablets
taken during the preceding 48 h.
WOMAC pain responder rate was deﬁned as an improvement in
WOMAC pain score of at least 40% vs baseline and an absolute
improvement of at least ﬁve points22. Patients were classiﬁed as an
OMERACT-OARSI responder (proposition D)23 if they achieved a
50% reduction and an absolute improvement of 4 (for WOMAC
pain) or 14 (for WOMAC physical function), or if they demonstrated
improvement in two out of three parameters as follows: a 20%
reduction and an absolute improvement of 2 (WOMAC pain), 7
(WOMAC physical function) or 1 (for patient assessment of global
status).
Safety analysis
The number and percentage of patients who reported adverse
events (AEs) was summarized using MedDRA terminology. AEs
were also classiﬁed by intensity (mild, moderate or severe) and
relationship to the study treatment.
Statistical methods
All statistical analyses were performed using SAS software,
with two-sided statistical tests and a signiﬁcance level of 5%.
Analysis populations and imputation methods
The safety population comprised all subjects who received any
randomized study treatment. The primary population for all
effectiveness analyseswas the ‘full analysis population’ (FAP)which
comprised subjects from the safety population with a baseline and
at least one post-treatment WOMAC pain score assessment. The
evaluable population (EP) consisted of subjects from the FAP with
no major protocol violations and not withdrawn prematurely. Two
EPs were deﬁned: one at 12 weeks (EP12) and one at 26 weeks
(EP26).
Multiple imputation (MI) was used to predict missing WOMAC
pain values for the FAP. Treatment group, priorWOMAC pain scores
and all baseline factors signiﬁcantly related to post-treatment
WOMAC pain score (KellgreneLawrence score and WOMAC phys-
ical function score) were included in the imputation regression
model. Last observation carried forward (LOCF) and baseline
observation carried forward (BOCF) imputationmethods were used
for sensitivity purposes, for WOMAC pain score analyses. LOCF was
the primary imputation method for all other endpoints. All EP re-
sults and data for the OLE were based on observed cases (OC) only.
Primary effectiveness analysis
The primary effectiveness endpoint was WOMAC pain
responder rate, an outcome not used in trials demonstrating the
efﬁcacy of MPA6. Non-inferiority of NASHA to MPA was assessed at
12 weeks using a two-sided 95% CI; the criterion for non-inferioritywas the lower bound of the CI for treatment difference
(NASHA  MPA) being above 15%.
Secondary effectiveness analyses
The superiority of NASHA to MPA was to be assessed if non-
inferiority was demonstrated. Superiority was to be declared if
the lower bound of the CI for treatment difference in responder rate
was greater than zero. WOMAC pain score was analysed for the FAP
with an MI approach.
Further secondary effectiveness outcomes included: WOMAC
pain responder rates (at time-points other than 12weeks), WOMAC
pain score, WOMAC physical function score, WOMAC stiffness
score, patient assessment of global status, physical activity assess-
ment, functional mobility assessment (‘Get up and go’ and
‘10-m timed walk’), OMERACT-OARSI responder rate and use of
rescue medication. Effect-sizes were calculated for the three
WOMAC domains as product difference in mean change from
baseline divided by the pooled standard deviation (SD).
Sample size estimation
The sample size calculation was based on a non-inferiority
margin of 15% and an assumed percentage of subjects responding
to each treatment of 45%. The number of subjects required for 80%
power to show that the two-sided 95% CI of the treatment differ-
ence lies above the non-inferiority margin was 180 per treatment
group. Assuming a drop-out rate of 20%, a minimum of 432 patients
were to be included.
Results
Subjects
442 participants were enrolled into the study; 221 were treated
with NASHA and 221 with MPA. At 26 weeks, 342 patients elected
to receive open-label NASHA, 163 from the NASHA group and 179
from the MPA group (Fig. 1).
For the blinded phase, more patients in the NASHA group than
in the MPA group had synovial ﬂuid aspirated at the time of in-
jection (NASHA: 15.6%; MPA: 8.8%, P ¼ 0.04) and there was a sta-
tistically signiﬁcant 2.3 cm difference in the height of female
subjects between the two groups (NASHA: 164.8 cm, MPA:
162.5 cm; P ¼ 0.019). As shown in Table I, there were no other
statistically signiﬁcant differences in demographic or other baseline
characteristics between the two study groups. Also, there were no
signiﬁcant baseline differences between patients who did or did
not receive NASHA at 26 weeks.
Effectiveness
Blinded phase (0e26 weeks)
The primary effectiveness objective was met, withWOMAC pain
responder rates at 12 weeks in the FAP demonstrating NASHA to be
non-inferior to MPA (NASHA: 44.6%; MPA: 46.2%; 95% CI of
difference: 11.2%; þ7.9%). WOMAC pain responder rates at weeks
6, 12 and 18 remained comparable between NASHA and MPA. Be-
tweenweeks 18 and 26, the WOMAC pain responder rate remained
stable in the NASHA group, while there was a decrease in the MPA
group over this period [Fig. 2(A)]. Sensitivity analyses of WOMAC
responder rates (LOCF, BOCF, OC, EP) all showed NASHA to be non-
inferior to MPA at all time-points [Fig. 2(B)]. Superiority was not
demonstrated at any time.
Secondary analysis ofWOMAC pain score over the ﬁrst 26 weeks
demonstrated that MPA provided early improvements in pain, with
the improvement reaching a maximum at 6 weeks and declining
thereafter until 26 weeks. In comparison, NASHA was associated
Fig. 1. Patient disposition. EP12/26, evaluable population at 12/26 weeks.
Table I
Patient demographics and baseline characteristics for the blinded phase (FAP)
Variable NASHA (n¼ 218) MPA (n ¼ 215)
Age in years [mean (SD)] 61.9 (9.6) 61.5 (9.9)
Female:male [n (%)] 111:107 (51:49) 102:113 (47:53)
Height [mean (SD)]
Female* 164.8 (7.1) 162.5 (7.1)
Male 176.6 (7.5) 177.8 (8.7)
BMI [mean (SD)] 28.2 (4.2) 28.3 (4.1)
Race [n (%)]
Caucasian 208 (95.4) 208 (96.7)
Black 4 (1.8) 1 (0.5)
Asian 4 (1.8) 5 (2.3)
Hispanic 0 (0) 1 (0.5)
Other 2 (0.9) 0 (0)
Duration of OA in years [mean (SD)] 4.7 (5.4) 4.9 (6.3)
KellgreneLawrence scorez
II [n (%)] 71 (32.6) 85 (39.5)
III [n (%)] 147 (67.4) 130 (60.5)
WOMAC pain score [mean (SD)]z 10.1 (2.2) 10.0 (2.3)
WOMAC physical function score [mean
(SD)]
31.0 (9.7) 29.5 (9.8)
Get-up-and-go test [mean (SD)] 9.9 (2.7) 10.0 (3.3)
Timed 10-m walk test [mean (SD)] 9.8 (3.5) 10.2 (4.5)
Synovial ﬂuid aspiratedy [n (%)] 34 (15.6%) 19 (8.8%)
NSAID or analgesics for OA at baseline [n (%)] 139 (63.8) 119 (55.3)
Previous treatment with IA steroids [n (%)]z 62 (28.4) 60 (27.9)
Previous treatment with IA HA [n (%)]z 18 (8.3) 27 (12.6)
Previous arthroscopy/knee surgery [n (%)]z 74 (34.1) 63 (29.3)
* Signiﬁcant difference was noted between groups (P¼ 0.019, two-sample t-test).
y Fluid aspirated from the study knee immediately before injection of study
medication, a signiﬁcant difference was noted between groups (P ¼ 0.04, Fisher’s
exact test).
z Relating to the study knee.
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observed between 6 and 26 weeks. When analysing WOMAC pain
score using the pre-speciﬁed repeated measures model, the
improvement from baseline was larger for NASHA than MPA at
week 26 (P ¼ 0.034) [Fig. 2(C)]. As shown in [Fig. 3(A)], the effect
size favoured NASHA from 12 to 26 weeks.
Results for the remaining secondary effectiveness variables over
the 26-week double-blind follow-up period were similar, with
NASHA eliciting greater improvements than MPA at weeks 12, 18
and 26 in WOMAC physical function [Fig. 3(B)] and WOMAC stiff-
ness [Fig. 3(C)]. For ‘Get-up-and-go’, ‘10-m timed walk’, and patient
global assessment, improvements from baseline were evident in
both treatment groups throughout the 26-week blinded phase,
with no signiﬁcant between-group differences. For physical activ-
ity, no signiﬁcant differences were evident between groups. How-
ever, OMERACT-OARSI responder rates were signiﬁcantly different
at 6 weeks (higher response rate in the MPA group, P ¼ 0.0138) and
at 26 weeks (higher response rate in the NASHA group, P ¼ 0.0237)
(Fig. 4). There were no signiﬁcant between-group differences in the
use of rescue medication.
Open-label extension (26e52 weeks)
Patients who received NASHA at 26 weeks showed higher
WOMAC pain responder rates at 39 and 52 weeks than at 26 weeks
[Fig. 5(A)]. The extent of improvement, approximately 10 percent-
age points, was similar whether patients initially received NASHA
or MPA. The responder rate was lower in the MPA group than the
NASHA group at 26 weeks and this difference was maintained at 39
and 52 weeks, with statistical signiﬁcance at 39 weeks. Similar
results were observed with WOMAC pain scores [Fig. 5(B)]. Mean
Fig. 2. A)WOMAC pain responder rates (standard error) for the blinded phase of the study (FAP,MImodel).B)Difference (NASHAMPA) inWOMAC pain responder rate (95% CIs):
primary (FAP, MI) and secondary analyses (FAP, LOCF; FAP, OC; FAP, BOCF; evaluable population at 12 weeks [EP12], OC and EP26, OC). C) WOMAC pain scores (95% CIs) following
double-blind treatment with either NASHA or MPA for each visit to 26 weeks (FAP, MI, repeated measures model). *P ¼ 0.034. EP12/26, evaluable population at 12/26 weeks.
Fig. 3. Effect-sizes for WOMAC domains with 95% CIs during the blinded phase of the
study. A) WOMAC pain. B) WOMAC physical function. C) WOMAC stiffness.
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decreased by approximately one point between 26 and 39 weeks in
both the NASHAeNASHA and MPAeNASHA groups, and both
groups showed a small additional decrease between 39 and
52 weeks. WOMAC physical function [Fig. 5(C)] and WOMAC stiff-
ness [Fig. 5(D)] demonstrated similar improvement following the
injection of NASHA at 26 weeks. Sustained increases in OMERACT-
OARSI responder rates were observed in both of the groups thatFig. 4. OMERACT-OARSI responder rates during the blinded phase of the study.received the 26-week NASHA injection, with 52-week responder
rates of 74.0% in the NASHAeNASHA group and 65.7% in the MPAe
NASHA group (Fig. 6).
A minority of patients chose not to receive a second injection at
26 weeks (NASHA: n ¼ 31; MPA: n ¼ 17). Continuing improvement
from baseline was observed among these patients, reﬂecting the
fact that they did not feel the need for a second IA treatment.
Safety results
Blinded phase (0e26 weeks)
During the blinded phase, 894 AEs were reported: 462 events
among patients in the NASHA group (172/221 patients) and 432
events among patients in the MPA group (156/221 patients). There
were 15 serious AEs (nine in the NASHA group, six in the MPA
group), none of which were considered related to study treatment.
The number of treatment-related AEs was 64 in the NASHA group
(48/221 patients), and 15 in the MPA group (15/221 patients).
Arthralgia was the most common treatment-related AE in both
study groups, with injection site pain, joint stiffness and joint
swelling also occurring in more than 1% of patients (Table II). Most
treatment-related AEs were reported within 3 days of injection
(NASHA: 48/64 cases, MPA: 8/15 cases) and resolved within 2e3
weeks (NASHA: mean 17.5 days, MPA: mean 15.5 days).
Open-label extension (26e52 weeks)
During the OLE, 328 AEs were reported: 160 in the NASHAe
NASHA group (96/163 patients) and 168 in the MPAeNASHA group
(94/179 patients). The nature of AEs was similar to that in the
blinded phase: no allergic sensitivities were observed, arthralgia
was the most common treatment-related AE, and joint stiffness,
joint swelling and musculoskeletal discomfort were observed in
more than 1% of patients (Table II). Consistent with the double-
blind phase, there were no treatment-related serious AEs. Also,
no allergic reactions to the second injection were observed.
Discussion
In this comparison of IA NASHA with a corticosteroid, NASHA
was well tolerated and demonstrated to be non-inferior to MPA
throughout the 26-week, double-blind phase of the study. Little
deterioration in WOMAC responder rate was observed between 12
and 26 weeks in the NASHA group, whereas signiﬁcant deteriora-
tion was observed in the MPA group between 18 and 26 weeks.
Open-label treatment with NASHA at 26 weeks provided im-
provements lasting to 52 weeks and demonstrated that NASHA
provides beneﬁt in patients previously treated with corticosteroid.
By demonstrating non-inferiority vs MPA, this study provides
level one evidence that NASHA should be considered as a treatment
option for knee OA. Most evidence supporting the efﬁcacy of IA
corticosteroids for knee OA has been obtained in patients with
KellgreneLawrence grade II or III6. For the present study, patients
with the same severity of knee OAwere recruited to ensure that the
outcomewould be applicable to patients most likely to beneﬁt from
IA corticosteroid therapy. With respect to WOMAC pain responder
rate, MPA showed activity to 18weeks post-treatment. This result is
consistent with high-quality studies showing that IA injection of
corticosteroid provides statistically signiﬁcant improvement in
symptoms at 16e24 weeks18, although this treatment is generally
perceived to have a shorter duration of action. In a meta-analysis of
corticosteroids and HA, corticosteroids demonstrated earlier
effectiveness with a short duration, while HA demonstrated a
slower time to onset of effectiveness but longer lasting pain relief5.
The WOMAC pain data from this study indicate the same trends
[Fig. 2(C) and Fig. 3(A)]. The ﬁrst evaluationwas at 6 weeks and it is
Fig. 5. Outcomes for each visit to 52 weeks among patients receiving NASHA treatment at 26 weeks (OLE analysis population, observed cases). Arrows indicate the 26-week
timepoint for open-label treatment with NASHA. A) WOMAC pain responder rates (standard error). Number of observed values (NASHAeNASHA/MPAeNASHA) at 6 weeks
and 12 weeks: 162/178; 18 weeks: 161/178; 26 weeks: 162/178; 39 weeks: 154/171; 52 weeks: 150/169. B) WOMAC pain scores (standard error). Number of observed values
(NASHAeNASHA/MPAeNASHA) at 6 weeks and 12 weeks: 162/178; 18 weeks: 161/178; 26 weeks: 162/178; 39 weeks: 154/171; 52 weeks: 150/169. C) WOMAC physical function
scores (standard error). Number of observed values (NASHAeNASHA/MPAeNASHA) at 6 weeks and 12 weeks: 161/177; 18 weeks: 161/178; 26 weeks: 162/176; 39 weeks: 154/171;
52 weeks: 150/168. D) WOMAC stiffness scores (standard error). Number of observed values (NASHAeNASHA/MPAeNASHA) at 6 weeks and 12 weeks: 162/178; 18 weeks: 161/
178; 26 weeks: 162/178; 39 weeks: 153/171; 52 weeks: 150/169. *P ¼ 0.039.
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effectiveness cross-over point for HA and corticosteroid in the
meta-analysis was at 4 weeks, vsw12 weeks in the current study.
The size and quality of the current study suggest that it is likely to
provide a more realistic view.Fig. 6. OMERACT-OARSI responder rates for each visit to 52 weeks among patients
receiving NASHA treatment at 26 weeks (OLE analysis population, observed cases).
Arrows indicate the 26-week timepoint for open-label treatment with NASHA. Number
of observed values (NASHAeNASHA/MPAeNASHA) at 6 weeks and 12 weeks: 162/178;
18 weeks: 161/178; 26 weeks: 162/178; 39 weeks: 154/171; 52 weeks: 150/169.Lack of allergic reactions to the second injection shows a lack of
increased sensitivity to the device; this answered the ﬁrst of the
two queries relating to the OLE. Regarding the second query, im-
provements were observed in both groups following the second
injection. This suggests that further injections of NASHA may be
administered according to clinical need arising after the initial
treatment, and that symptomatic improvement may be expected.
The post-NASHA improvement inWOMAC pain responder rate was
smaller after the 26-week OLE injection than the increase after
initial treatment. This is in line with expectation, given the residual
effect of initial treatment. However, duration of response to the
second treatment appeared longer than after the initial injection.
Among patients receiving two NASHA injections, considerable re-
ductions from baseline in WOMAC pain score were evident at
26 weeks (w40%) and 52 weeks (nearly 50%). Sustained reduction
from baseline between 26 and 52 weeks was also observed among
patients receiving NASHA after MPA. These ﬁndings, together with
theWOMAC pain responder rate of 56% at 52 weeks in the NASHAe
NASHA group (OMERACT-OARSI responder rate of 74%), represent a
meaningful change in OA symptoms for most patients.
Unlike previous studies of NASHA for knee OA, the present trial
recruited patients without end-stage OA (KellgreneLawrence grade
IV), without clinical effusion at baseline and without signiﬁcant
pain from other joints. It is now recognised that HA is not generally
effective for end-stage OA or in patients with large clinical effu-
sions24e26. The presence of poly-articular pain appears to be a
Table II
AEs, related to the product or injection procedure, occurring in >1% of patients
(safety population)
NASHA* MPAy
Patients % Patients % P-valuez
Blinded phase
Arthralgia 38 17.2 7 3.2 <0.0001
Injection site pain 3 1.4 1 0.5 0.623
Joint stiffness 4 1.8 0 0 0.123
Joint swelling 5 2.3 1 0.5 0.216
Open-label extension
Arthralgia 30 18.4 31 17.3 NC
Joint stiffness 1 0.6 3 1.7 NC
Joint swelling 2 1.2 1 0.6 NC
Musculoskeletal
discomfort
3 1.8 0 0.0 NC
NC, not calculated.
* Blinded phase, n ¼ 221; open-label extension, NASHAeNASHA group, n ¼ 163.
y Blinded phase, n ¼ 221; open-label extension, MPAeNASHA group, n ¼ 179.
z Fisher’s exact test.
R. Leighton et al. / Osteoarthritis and Cartilage 22 (2014) 17e2524confounding factor in knee OA pain studies27. When these factors
were eliminated in a post-hoc analysis, the results were consistent
with the current study28. Single-injection NASHAwas shown in the
present study to provide a stable, long-term improvement in OA
symptoms. The duration of effect was consistent with the 4-week
half-life of NASHA and its prolonged residence time within the
joint. Although the precise mechanism of action of HA has yet to be
fully described, supplementation of HA through IA injection of
NASHA appears to offer the potential for sustained patient beneﬁts.
AEs were largely anticipated in nature, with a lack of differences
between NASHA andMPA regarding the type, onset and duration of
AEs. Arthralgia was the most common treatment-related AE, and
this is anticipated to occur among recipients of IA HA12,29,30. The
occurrence of arthralgia in the NASHA group did not affect the
WOMAC pain responder rate at 12 weeks. No systemic AEs or acute
ﬂare reactions were seenwith NASHA, and a second injection of the
product at 26 weeks appeared to be at least as well tolerated as the
initial injection.
The strengths of this study were the use of MPA control as a
pragmatic standard-of-care for knee OA, and the excellent conduct
of the study as shown by the very low drop-out rate (w90%
completion of the 26-week blinded phase). Similarity of patients’
baseline characteristics in the two study groups conﬁrms that the
1:1 randomization process was effective, and that post-treatment
between-group differences may be attributed to study medica-
tion. Additionally the WOMAC pain responder rate, a clinically
meaningful primary endpoint, has been used in few other studies.
The deﬁnition of the responder rate is an important consideration.
For example, responder rates based on absolute improvement are
likely to be higher among patients with more severe symptoms
than responder rates based on percentage improvement. In accor-
dance with a report from the Osteoarthritis Research Society In-
ternational Standing Committee for Clinical Trials, the primary
endpoint in this study was based on both percentage and absolute
improvement22. In a post-hoc analysis using a WOMAC pain
responder deﬁnition of 40% improvement and no requirement for
absolute change, the 26-week data showed a statistically signiﬁcant
beneﬁt with NASHA (responder rates: NASHA, 54%; MPA, 44%;
P ¼ 0.043). The lack of a saline control arm may be considered as a
limitation of this study but, at the time of designing the study, the
inclusion of such a control group was considered unethical. We
consider that the results are applicable to knee OA patients pre-
senting with mild to moderate structural changes and pain in the
absence of clinical effusion.
In conclusion, this study showed that NASHA is a valuable
treatment for knee OA, providing effectiveness that was non-inferior to MPA. It also indicated that the effect of NASHA is
longer lasting, with signiﬁcantly improved pain response at
26 weeks compared to MPA. NASHA is well tolerated in relation to
both primary and secondary injections, with most AEs being
anticipated and non-allergenic in nature.
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